Bastiano Sanna, EVP, Cell & Genetic Therapies at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 5,355 shares at $300.39 ($1.6M) on 2023-02-13, disclosed to the SEC on 2023-02-14.
Scheduled sale ($1.6M) by EVP, Cell & Genetic Therapies under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $294.33 | 902 | $265K | 16.7% |
| 2 | $298.26 | 4,340 | $1.3M | 81.2% |
| 3 | $300.39 | 113 | $34K | 2.1% |
| Total | $297.64 avg | 5,355 | $1.6M | 100% |
| Filing → |
| VRTX | SELL | 2023-04-14 | $4.9M | — | Filing → |
| VRTX | SELL | 2023-04-06 | $231K | — | Filing → |
| VRTX | SELL | 2023-03-20 | $1.7M | — | Filing → |